Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 46
- Registration Number
- NCT02185768
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
🇫🇷CHU - Hôpital François Mitterand, Dijon, France
🇫🇷Hôpital Edouard Herriot, Lyon, France
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia in RemissionAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 27
- Registration Number
- NCT02144675
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
Phase 2
Completed
- Conditions
- Acute Undifferentiated LeukemiaAcute Leukemia of Ambiguous LineageMixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise SpecifiedMixed Phenotype Acute LeukemiaMixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise SpecifiedAcute Bilineal LeukemiaAcute Biphenotypic LeukemiaRecurrent Mixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02135874
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Phase 2
Recruiting
- Conditions
- Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts 10 Percent or More of Bone Marrow Nucleated CellsBlasts 10 Percent or More of Peripheral Blood White CellsDe Novo Myelodysplastic SyndromeMyelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 508
- Registration Number
- NCT02115295
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02096055
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Terminated
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Bruno C. Medeiros
- Target Recruit Count
- 1
- Registration Number
- NCT02049801
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Duke University
- Target Recruit Count
- 19
- Registration Number
- NCT02046122
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Clinical Guidelines for APL Treatment
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT02020161
- Locations
- 🇪🇸
Hospital La Fe, Valencia, Spain
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 204
- Registration Number
- NCT02013648
- Locations
- 🇦🇹
Hanuschkrankenhaus, Wien, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹Universitätsklinik der PMU, Salzburg, Austria
Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT01958996
- Locations
- 🇫🇷
CHU de Poitiers, Poitiers, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath